Drug Trial Radar · NCT04839328
A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Jan 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
306
Actual
Start
Jan 20, 2022
Primary completion
Oct 25, 2022
Study completion Jul 28, 2023
Sponsor
- Lead sponsor
- Tianjin Hemay Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. After single asending dose and mutiple asending dose in health subjects. phase 2 results suggest Hemay005 60 mg BID has a higher curative effect trend,and adverse reactions were mild, so we choose 60 mg BID as Hemay005 phase 3 dosage And the patients with moderate to severe plaque psoriasis will be randomized into 2 cohorts(60mg BID and placebo) approximately 306 subjects will be enrolled (204 in 60mg BID and 102 in placebo). This study includes an 16-week treatment Period, then a 36-week Treatment Period without placebo.
Conditions
- Psoriasis
Interventions
60mg Hemay005Drug
Hemay005 is a small molecule PDE4 inhibitor.
PlaceboDrug
Placebos are the same as drugs, but contain no Hemay005.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75).Time frame: week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.